Potency-optimized CD28-activating bispecific antibody for the targeted treatment of Nectin-4 positive cancers

20254 citationsJournal Articlegold Open Access

Authors

Manpreet Kaur · Chrono Therapeutics (United States)

Katja Rüger · Chrono Therapeutics (United States)

Elaine C Chen · Chrono Therapeutics (United States)

Udaya S. Rangaswamy · Chrono Therapeutics (United States)

Laura Davison · Chrono Therapeutics (United States)

Stephanie Arteaga · Chrono Therapeutics (United States)

Ian E. Smith

Abstract

Our study reports the first CD28 bsAb targeting Nectin-4 and highlights the potential of CD28 × Nectin-4 bsAbs as a new immunotherapeutic modality. The findings support the clinical development of RNDO-564 in patients with locally advanced and metastatic UC and other Nectin-4 positive malignancies.

Topics & Keywords

Immune Cell Function and Interaction Immunotherapy and Immune Responses CAR-T cell therapy research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal for ImmunoTherapy of Cancer

Volume 13, Issue 4, pp. e011323-e011323

DOI: 10.1136/jitc-2024-011323

Field-Weighted Citation Impact: 3.34